Isthmin inhibits glioma growth through antiangiogenesis in vivo

Journal of Neuro-Oncology

Volumn 109, Issue 2, 2012, Pages 245-252

  Yuan, Bangqing ^a   Xian, Ronghua ^a   Ma, Jianfang ^a   Chen, Yujian ^a   Lin, Chuangan ^a   Song, Yaoming ^b  

^a FUZHOU GENERAL HOSPITAL   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antiangiogenesis; Glioma; Growth; Isthmin

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; CASPASE; ISTHMIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE; GLIOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; ISTHMIN GENE; MOUSE; NONHUMAN; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; GLIOMA; HUMANS; MICE; MICE, NUDE; MICROVESSELS; PROTEINS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866029831     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0910-8     Document Type: Article

References (35)

1. Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK et al (2009) Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 18:1061-1083
2. Germano IM, Binello E (2009) Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside. J Neurooncol 93:79-87
3. Mukherjee J, DeSouza LV, Micallef J, Karim Z, Croul S, Siu KW et al (2009) Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII. Cancer Res 69:8545-8554
4. Machein M, de Miguel LS (2009) Angiogenesis in gliomas. Recent Results Cancer Res. (Fortschritte der Krebsforschung) 171:193-215
5. Norden AD, Drappatz J, Wen PY (2008) Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 7:1152-1160
6. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A et al (2008) Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26:271-278
7. Shen TL, Park AY, Alcaraz A, Peng X, Jang I, Koni P et al (2005) Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol 169:941-952 (Pubitemid 41002870)
8. Feng Y, vom Hagen F, Pfister F, Djokic S, Hoffmann S, Back W et al (2007) Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thromb Haemost 97:99-108 (Pubitemid 46242391)
9. Nomiyama T, Zhao Y, Gizard F, Findeisen HM, Heywood EB, Jones KL et al (2009) Deficiency of the NR4A neuron-derived orphan receptor-1 attenuates neointima formation after vascular injury. Circulation 119:577-586
10. Chen D, Abrahams JM, Smith LM, McVey JH, Lechler RI, Dorling A (2008) Regenerative repair after endoluminal injury in mice with specific antagonism of protease activated receptors on CD34? vascular progenitors. Blood 111:4155-4164
11. Yokoyama U, Minamisawa S, Quan H, Akaike T, Jin M, Otsu K et al (2008) Epac1 is upregulated during neointima formation and promotes vascular smooth muscle cell migration. Am J Physiol 295:H1547-H1555
12. Rahimi N (2009) A role for protein ubiquitination in VEGFR-2 signalling and angiogenesis. Biochem Soc Trans 37:1189-1192
13. Kim HS, Lim SJ, Park YK (2009) Anti-angiogenic factor endostatin in osteosarcoma. APMIS 117:716-723
14. Nakai K, Rogers MS, Baba T, Funakoshi T, Birsner AE, Luyindula DS et al (2009) Genetic loci that control the size of laserinduced choroidal neovascularization. FASEB J 23:2235-2243
15. Pera EM, Kim JI, Martinez SL, Brechner M, Li SY, Wessely O et al (2002) Isthmin is a novel secreted protein expressed as part of the Fgf-8 synexpression group in the Xenopus midbrainhindbrain organizer. Mech Dev 116:169-172 (Pubitemid 34786420)
16. Xiang W, Ke Z, Zhang Y, Ho-Yuet Cheng G, Irwan ID, Sulochana KN, et al (2011) Isthmin is a novel secreted angiogenesis inhibitor that inhibits tumour growth in mice. J Cell Mol Med 15:359-374
17. Markovic DS, Vinnakota K, Chirasani S, Synowitz M, Raguet H, Stock K et al (2009) Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc Nat Acad Sci USA 106:12530-12535
18. Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS (2009) Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res 7:1756-1770
19. Kreisl TN (2009) Chemotherapy for malignant gliomas. Semin Radiat Oncol 19:150-154
20. Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V et al (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115:3512-3518
21. Agrawal A (2009) Butterfly glioma of the corpus callosum. J Cancer Res Ther 5:43-45
22. Wick W, Weller M (2009) Classification and management of anaplastic gliomas. Curr Opin Neurol 22:650-656
23. Nagai T, Tanaka M, Tsuneyoshi Y, Xu B, Michie SA, Hasui K et al (2009) Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta. Cancer Immunol Immunother 58:1577-1586
24. Yamanaka R (2009) Dendritic-cell-and peptide-based vaccination strategies for glioma. Neurosur Rev 32:265-273 discussion 273
25. La Rocca RV, Mehdorn HM (2009) Localized BCNU chemotherapy and the multimodal management of malignant glioma. Curr Med Res Opin 25:149-160
26. Moreno MJ, Ball M, Andrade MF, McDermid A, Stanimirovic DB (2006) Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel anti-angiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)-differentiated glioblastoma cells. Glia 53:845-857
27. Sathornsumetee S, Hjelmeland AB, Keir ST, McLendon RE, Batt D, Ramsey T et al (2006) AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res 66:8722-8730 (Pubitemid 44449189)
28. Zhang X, Jiang F, Kalkanis SN, Zhang Z, Hong X, Yang H et al (2007) Post-acute response of 9L gliosarcoma to Photofrinmediated PDT in athymic nude mice. Lasers Med Sci 22:253-259 (Pubitemid 47622120)
29. Martin V, Liu D, Gomez-Manzano C (2009) Encountering and advancing through antiangiogenesis therapy for gliomas. Curr Pharm Des 15:353-364
30. Wong ET, Brem S (2008) Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Nat Compr Cancer Netw 6:515-522 (Pubitemid 351760842)
31. Yang Q, Tian Y, Liu S, Zeine R, Chlenski A, Salwen HR et al (2007) Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 67:1716-1724 (Pubitemid 46383398)
32. Rossi V, Beffagna G, Rampazzo A, Bauce B, Danieli GA (2004) TAIL1: an isthmin-like gene, containing type 1 thrombospondinrepeat and AMOP domain, mapped to ARVD1 critical region. Gene 23:101-108 (Pubitemid 38759756)
33. Hayashi S, Itoh M, Taira S, Agata K, Taira M (2004) Expression patterns of Xenopus FGF receptor-like 1/nou-darake in early Xenopus development resemble those of planarian nou-darake and Xenopus FGF8. Dev Dyn 230:700-707 (Pubitemid 38993869)
34. Drouet L (2008) Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers. Pathol Biol 56:195-204
35. Lemmens L, Claes V, Uzzell M (2008) Managing patients with metastatic colorectal cancer on bevacizumab. Br J Nurs 17:944-949